Galegenimab, a newly developed agent, is sparking considerable anticipation within the cancer community. This innovative substance functions as an antagonist of TIGIT, a checkpoint protein, which https://dirstop.com/story28792244/galegenimab-a-promising-possibility-in-malignancy-therapy